IN-DATE
VPR-GW-17: CSI ViperWire Advance Guidewire 0.017" x 335cm
Sign in to add this product to your favorites!
| Price: | $30.00 $3.00 EACH |
|---|---|
| Quantity: | |
| In Stock: | 102 eaches |
| Status: | expired |
Related Items
QUICK VIEW
| VPR-GW-14 - Size: 0.014" $30.00 $21.00 EACH CSI ViperWire Advance Guidewire 0.014" x 335cm Expired Units in stock: 74 | Order Qty |
QUICK VIEW
| VPR-GW-14 - Size: 0.014" $149.00 $104.30 per box of 5 CSI ViperWire Advance Guidewire 0.014" x 335cm Expired Units in stock: 8 box of 5 | Order Qty |
|
QUICK VIEW
| VPR-GW-17 - Size: 0.017" $150.00 $15.00 per box of 5 CSI ViperWire Advance Guidewire 0.017" x 335cm Expired Units in stock: 12 box of 5 | Order Qty |
Additional Details
Abbott CSI ViperWire Advance™ & ViperWire Advance™ with Flex Tip Peripheral Guide Wires
ViperWire Advance™ and ViperWire Advance™ with Flex Tip Peripheral Guide Wires are designed specifically for the Diamondback 360™ Peripheral Orbital Atherectomy Systems to facilitate proper device placement within the peripheral artery to enable orbital gain during PAD treatment.
AccessGUDID Info
- FDA Product Code: MCW
- FDA Product Code Name: Catheter, Peripheral, Atherectomy
- GMDN Term Code: 58115
- GMDN Term Name: Peripheral vascular guidewire, manual
- GMDN Term Description: A long, thin wire intended to be percutaneously placed into the peripheral vasculature (not heart or central nervous system) to function as a guide for the introduction of devices (e.g., catheters). It is made of metal (e.g., stainless steel, Nitinol), with or without coating, and is available in a variety of distal tip designs. It is intended to be used for percutaneous angiography, angioplasty, rotational atherectomy and thrombectomy, drainage, and other diagnostic and interventional procedures. It may include devices used to facilitate manipulation (e.g., torque device). This is a single-use device.
Manufacturer
Cardiovascular Systems, Inc. (CSI), now a part of Abbott, specialized in innovative solutions for the treatment of peripheral and coronary artery disease through its proprietary orbital atherectomy systems. CSI’s flagship technologies include the Diamondback 360® Peripheral Orbital Atherectomy System and the Diamondback 360® Coronary Orbital Atherectomy System, both designed to modify calcified plaque and improve vessel compliance prior to stent placement or balloon angioplasty.
These systems use a diamond-coated crown that orbits within the vessel, sanding away plaque while preserving healthy tissue and facilitating better device delivery. CSI’s focus on challenging arterial disease—particularly in heavily calcified lesions—made it a valuable addition to Abbott’s vascular portfolio following its acquisition in 2023, further expanding minimally invasive treatment options for complex cardiovascular cases.
